Walvax Biotechnology Co., Ltd. is principally engaged in the research, development, production and distribution of human vaccine products. The Company primarily provides haemophilus influenzae B vaccines, which are applied in the prevention of meningitis, pneumonia, septicemia, cellulitis, arthritis and pharyngitis caused by Hib, as well as group A and group C meningococcal polysaccharide vaccines, which are applied in the prevention of diseases caused by group A and group C meningococcal polysaccharide, such as cerebrospinal meningitis and septicemia. The Company distributes its products primarily in domestic market.

Walvax Biotechnology produces Hib Vaccine (a vaccine for viral hepatitis) and A, C Meningococcal Polysaccharide Conjugate Vaccine, which made up 65.26% and 13.59% of its 2009 revenues, with annual production capacity of eight million and five million vaccines, respectively. The company's clients are mostly disease control centers and medicine dealers.